



A Short Review on Monkey Pox Disease

Obaidullah Nasih¹, Rahama Sanusi Karama^{1*}, Chika Chizitelu Madekwe², Chinelo Chioma Madekwe², Shikha Gupta³

1524

***Corresponding Author:** - Rahama Sanusi Karama

¹ Department of Public Health, School of Allied Health Sciences, Noida International University, Delhi NCR-India

² Department of General Medicine, Vinnytsia National Medical University, Ukraine

³ School of Nursing, Noida International University, Delhi-NCR India

Abstract

Monkeypox is caused by the monkeypox infectious agent, which is a member of the Poxviridae family and originally belonged to the orthopoxvirus family. Further human infections in this family append variola virus (which causes smallpox), cowpox virus, and vaccinia virus. Smallpox infection. Monkeypox infection recommence to conceal in the humid wet Central and West African woodlands. Over 40 years after smallpox was eradicated and the illness was firstly reported in laboratory monkeys in 1958, nonetheless, the very first human case in point was discovered During the year 1970, a 9-month-old boy in the Democratic Republic of the Congo (DRC) Sign and symptom of monkey pox are Fever, headache, muscular pains, backache, enlarged lymph nodes, chills, and tiredness. It is inherited from one person to other person through close contact with infectious material from either a contaminated source of singular's skin injuries, and by respiratory droplets in continued contact in face-to-face and fomites. Monkeypox could only be treated definitively in a laboratory, where the virus may be recognized using a variety of assays. Keep off touching any point that have come get into touch with a sick or ill animal, such as bedding. Unconnected unclean ill from all of those who could be infected at risk of contamination. As a result, gaining a better knowledge of this common zoonosis will aid in developing better preventative techniques and relieving human sickness. There are no permission treatments for HMP, Hence, the smallpox vaccination is current effective in inhibiting the infection.

DOI Number: 10.14704/nq.2022.20.9.NQ44176

Neuro Quantology 2022; 20(9):1524-1529

INTRODUCTION

The monkeypox virus is a part of the orthopoxvirus species in the Poxviridae genealogy, causes monkeypox. Further human infections in this form add variola virus (which causes smallpox), cowpox virus, and vaccinia virus. Smallpox illness results in long-term resistance; recurrent smallpox attacks are only approximately 1 in 1000 for the next 15–20 years. [1] The monkeypox virus keep going to obscure in the humid Central and Western Tropical rain woodlands. Africa over 40 years after smallpox was eradicated [2]. The illness was first recognized in laboratory monkeys in 1958, nonetheless, the very first human case in point was discovered during the year 1970, a 9-month-child in the Democratic Republic of the Congo (DRC). [3][4][5][6][7]. Fever, rash, and lymphadenopathy identifying the clinical

circumstances. Inflammation of the lungs tissue (pneumonitis), encephalopathy (disease of the brain), visual keratitis, and future bacterial infections are also consequences of monkeypox (MPV). [8]

Although orthopox.V antibodies have been found in a variety of gnawer and monkey groups in Central and West Africa, exist monkeypox virus (MPXV) has been identified only twice in enzootic animals, as well as the final source is unknown. And the animal grows unwell after an exposure, with an average time of incubation of 12 days, and has the ability to spread the virus to people if they are in close contact. In 1996-1997, the DRC recorded human-to-human disease transmission that resulted in an outbreak. [9]. Studies that will bring solutions and understanding of endemic like monkeypox



impact on both the children and adult's psychological as well as physical health and development may vividly support/ guide strategies and prevent the children especially from possible damage and overall thrive and advancement of positive child development, and intervention of further research about the disease, and betterment informed information as well as counseling and educating the parent about their children health [32][33].

	1970-1990	1991-1999	2000-2009	2010-2018
Congo, Democratic Republic of (former Zaire)	386 verified cases (27) + 2-5	511	Not fully enumerable	Not fully enumerable
Government of the Central African Republic	6 verified	Not-Applicable	4	At least 68 to 29 verified cases
Cameroon	2 verified	4 to 1 verified	Not-Applicable	16 to 1 verified
Nigeria	10 to 3 verified	Not-Applicable	Not-Applicable	244 to 101 verified
Ivory Coast	2 verified	Not-Applicable	Not-Applicable	Not-Applicable
Liberia	4 verified	Not-Applicable	Not-Applicable	2 verified
Sierra Leone	1 verified	Not-Applicable	Not-Applicable	At least 2 to 2 verified
Gabon	1-10 one verified case	Not-Applicable	Not-Applicable	Not-Applicable
USA	Not-Applicable	Not-Applicable	47 to 37 verified, 10 probable	Not-Applicable
Republic of Congo	Not-Applicable	Not-Applicable	12 to 3 verified, 8 probable	98 to 9 verified
South Sudan	Not-Applicable	Not-Applicable	49 to 10 verified, 9 probable cases	Not-Applicable

Table 1 | Human Monkeypox Infections Recorded Worldwide From 1970 To 2018.

As of 13:00 on May 21, WHO had received reports of 92 laboratory recorded cases of monkeypox and 28 doubted cases of monkeypox with investigations underway from 12 subscriber Nations that are particularly not endemic for the monkeypox virus, spread over three WHO regions (Table 2, Figure 1)? Too far, no deaths have been linked to the incident. Human monkeypox incidences recorded worldwide from 1970 to 2018. [11]

Table2. Monkeypox incidence in non-endemic countries reported to WHO between 13 to 21 May 2022 as at 13:00

Country	Confirmed	Suspected
Australia	1-5	24
Belgium	1-5	1-5
United states America (USA)	1-5	-
Canada	1-5	11-20
Spain	21-30	6-10
France	1-5	1-5
United Kingdom (UK)	21-30	-
Germany	1-5	-
Italy	1-5	-
Netherland	1-5	-
Portugal	21-30	-
Sweden	1-5	-
TOTAL	92	28




Figure 1. Between 13 and 21 May 2022, the geographic

spread of verified and cases reported of monkeypox in non-endemic countries, as at 13:00. [12]

EPIDEMIOLOGY

Those who living in or around forest environments may be affected in a limited or passive manner, potentially leading to the subclinical stage illness. The illness is uncommon and is only found in Western and Central African damp forests. Monkeypox has been identified in humans in 1970, after smallpox had been eradicated, presumably as a result of the infection's future unmasking. Although In the DRC, surveillance records from 1981 to 1986 recorded 338 cases (Out of a population of 5 million during 1982). The attack rate in the DRC during the 1996-1997 outbreaks was 22 infections per 1000 people. Since 1978, no human illness with monkeypox has been reported in West Africa, in 2003, 11 cases and one fatality were recorded from the Sudan and the Democratic Republic of the Congo (DRC) reported 10 incidents with no deaths in 2005. [13] In three African nations between 2000 and 2009 (South Sudan and Democratic Republic of the Congo DRC), however, cases were detected in seven nations of Africa between 2010 and 2019(Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Liberia, Nigeria, Sierra Leone, and the Republic of the Congo). Monkeypox has had the greatest impact on the Democratic Republic of the Congo, and no other state has recorded over the last five decades, there have been several cases of monkeypox. Nigeria is the second most crush country, with 181 confirmed and likely cases since the incidence began in September 2017. The Nigeria CDC report lists 183 cases but, two Nigerian infections were confirmed in Israel and Singapore. [14]

ETIOLOGY

Monkeypox virus is a constituent of the Poxviridae family, chordopoxvirinae subfamily, orthopoxvirus type, and monkeypox infection type. The monkeypox infection seems to be rather huge under electron microscopy (Nanometers 200-250). Poxviruses have a brick-like appearance. Having a linear double-stranded DNA genome covered in a lipoprotein envelope. Pox viruses have all the essential replicating, transcription, building, and transit proteins in

their genome, except for their mRNA translation dependency on host ribosomes [15]

SIGN AND SYMPTOM

Human monkeypox is an uncommon zoonotic infection that is produced by an orthopoxvirus and distinguish by smallpox-similar signs or symptoms. [16] Like Fever, headache, muscular pains, backaches, some of the symptoms include swollen lymph nodes, cold, and exhaustion. That might occur. A rash commonly first appears on the face, but it can spread to further parts of the body, including the genitals. Before developing a scab that eventually breaks off, the rash will go through many phases. In agreement with the European Center for Disease Prevention and Control (ECDC), recent instances between homosexual men have featured genital sores. [17] The basic or main diagnose between smallpox and monkeypox symptoms is that smallpox symptoms are more severe. And that monkeypox causes lymphadenopathy whereas smallpox does not. Monkeypox takes it usually (7–14) days to mature, but it might take it from (5 to 21) days. [18]

The virus can be split up into (2) stages:

- 1) The assault span (0 to 5 days)
- 2) The skin discharge span (between 1to3 days after presence of fever)

The assault span:

The symptoms of the sickness consist of fever, headache, muscular pains, backache, enlarged lymph nodes, chills, and tiredness.

The skin discharge period:

Within 1-3 days of the first the onset of fever, the patient improves a rash, which commonly arises on the face and distribute to other areas of the body. The cheeks, front of the hands (palms), and down side of the feet (soles) are the most afflicted areas. 3 weeks may be necessary before the crusts are totally removed. The following lesion improvement are spotted within the following phases:

- Rash (any area of irritated or swollen skin on your body)
- Macules (flat, distinct, discolored area of skin)
- Papules (papule elevated, solid, palpable lesion that is <1 cm)

- Vesicles (fluid becomes trapped under the top layer of skin epidermis)
- Pustules (bulging patch of skin that's full of yellowish fluid called pus)
- Scabs (scabs are patches of dry, tough skin)

Stage of MPV	clarification	Delegation	Duration stage
Rash	It is an extra wide skin lesion that might include many lesions with primary and secondary methods.		1 to 2 days
Macules	Smooth injury < 1 cm in diameter		1 to 2 days
Papules	Raised injury that is < 1 cm in width		1 to 2 days
Vesicles	Small liquid covering injury that is < 0.5 cm		1 to 2 days
Pustules	Vesicle encasing pustular substance It might be white or yellow. Is not always contaminated		5 to 7 days
Scabs	During the wound healing Reconstruction phase, a hard layer forms on the skin.		7 to 14 days

1526

The illness typically lasts 2 to 4 weeks. Monkeypox has seen to kill up to one in every ten people who catch the disease in African countries. [19]

Clinical Features monkeypox, Smallpox, and Varicella Virus

Specification	Monkeypox	Smallpox	Varicella
Time span			
Incubation span	7 to 17 days	7 to 17 days	10 to 21 days
Prodromal span	1 to 4 days	1 to 4 days	0 to 2 days
From the formation of lesions through ulcerations, there is a brief period of rash.	14 to 28 days	14 to 28 days	10 to 21 days
Symptoms			
prodromal pyrexia	detected	Yes	If a slight fever is present, it is uncommon.
pyrexia	Yes, time and again between 38.5°C and 40.5°C	Yes, time and again >40°C	Yes, up to 38.8°C
Restlessness	detected	detected	detected
Pain in the head (headache)	detected	detected	detected
Enlarge lymph nodes	detected	No	No
Injuries on palms or soles	detected	detected	Rare
Injury distribution	eccentric	eccentric	eccentric
Injury presence	Umbilicated tight, solid and deep, well confined	Umbilicated tight, solid and deep, well confined	Superficial, uneven margins, "dew drop on a rose petal"



Injury progression	Injuries are frequently in one stage of growth on the body, with each stage lasting 1–2 days.	Lesions are frequently in one stage of growth on the body, with each stage lasting 1–2 days.	Injuries are often in various stages of improvement on the body; fast progression
--------------------	---	--	---

Table 3. Key Clinical difference between Features of Smallpox, Monkeypox, and Varicella. [20]

TRANSMISSION

MPX is passed from person to person by intimate contact with infectious material from an ill individual's skin lesions, and via respiratory secretions and fomites in long time face-to-face touching base. The number of human MPX diagnosed cases during the presence of the disease in the midst of homosexual (gay) (MSM), in addition, the form of giving injuries in some occurrence, implying that transference took place with sexual contact. Although transmission by unbroken skin contact is unlikely, it cannot be ruled out. Several sexual activities that may be prevalent in specific segment of the MSM population (e.g., having several frequent sexual interactions and/or numerous sexual buddies, be present to chem sex get-togethers) may help to spread monkeypox. [21]

DIAGNOSE

Although monkey pox's clinical manifestations is so related to chickenpox and smallpox's, a precise diagnosis is critical for treating spontaneous sickness or spotting a potential bioterrorism incident early [22] And Samples from skin lesions, including such vesicular biopsies, drainage, or crusts, should be maintained in an arid, sterilized tube (no viral transport medium) and saved chill for laboratory research. An oropharyngeal or nasopharyngeal swab should be used to acquire a viral culture. Skin cultures from vesiculopustular rash or a trial of the ridge of a skin vesicular wound are useful for analysis. Standard laboratories with high control technologies are essential to establish a definite identification using electron microscopy, culture, and molecular analysis credentials by PCR and sequencing. Serological testing needs important and improving samples to identify MPXV-specific IGM approximately 5 days following the presentation, or IgG after 8 days. Monkeypox can be identified definitively only in a laboratory, where the virus may be identified using a variety of diagnostics.

- By Polymerase chain reaction (PCR) [23]

- By Enzyme-linked immunosorbent assay (ELISA)
- By Antigen finding trials
- By Virus isolation by cell culture
- By Cross-adsorbed virus neutralization
- By Immunofluorescence or hem agglutination inhibition assays,
- By Immunoblotting or Western blotting [24]

PREVENTION

Trying to prevent moneybox spread by limits on animal exchange or preventing the mobility of minor African animals and monkeys may be effective in limiting the virus's spread outdoor of Africa. Animals that are potentially dirtied may be separated from other animals and placed in emergency quarantine. Avoid coming into touch with all animals who may have come into exposure to the virus. Keep away from handling any bedding or other resources that have comes in touching base with a sick animal. Anyone who have been polluted should be separated from others who may be at danger of contamination. Exercise tremendous hand hygiene after coming into touching base with compromised animals or humans. For example, you can wash your hands with soap and water, such as, by use of an alcohol-based hand sanitizer. When treating patients, use personal protection equipment is always recommended. [25]

TREATMENT

There is worry that the etiological cause of smallpox, variola infection or virus, it could be working as a biological weapon system. As a result, several governments are keeping (vaccinia virus-based) smallpox vaccine. Even if the effectiveness of the smallpox vaccine for prevention is widely accepted, nothing is known regarding its efficiency when utilized after viral exposure. Antiviral therapy using any of the antiviral medications and applying various systemic therapy and remedy schedules within 24 hours after fatal intratracheal MPXV infection resulted in considerably decreased mortality and cutaneous moneybox lesions. [26] which are presently not accepted treatment for human monkeypox; however, brincidofovir and tecovirimat, 2 orally existing meds, have been admissible by the American Food in the treatment of smallpox through the event of a bioterrorism offense, and the United Kingdom



has also agreed the usage of brincidofovir and tecovirimat to treat human monkeypox. [27]

Although there are no licensed medicines for human monkeypox (HMPV), the smallpox vaccination can offer protection compared to the disease. Human vulnerability to monkeypox virus infection has grown after widespread immunization was discontinued in the 1980s.

Cidofovir

Cidofovir is a potent antiviral medication that is used to treat a variety of virally induced skin diseases. It is used to treat skin illnesses caused by DNA viruses, either topically or intravesicular. All DNA viruses, together with Herpes, Adeno, Polyoma, Papilloma, and Poxviruses, are resistant to it. The inhibitory effects of cidofovir have been recognized to be effective against smallpox, cowpox, monkeypox, camelpox, and molluscum necessary to provide additional. [28]

Smallpox Vaccine

When given before being exposed to monkeypox, the smallpox vaccination is effective in protecting people from the disease. To avoid disease development, the vaccination should be given within four days of exposure, according to the CDC. Vaccination given 4 to 14 days following exposure can help with clinical sign but not inhibit the disease. [29]

Tecovirimat (ST-246)

ST-246 is effective in the treatment of orthopoxvirus-related sickness. The drug was found to be safe and tolerable in human clinical studies, with just minor adverse effects. Tecovirimat is now undergoing clinical testing, and the US Food and Drug Administration recently granted authorization to conduct Phase II trials. Tecovirimat was in general well accepted in time I trials, with no significant side effects. [30]

Vaccinia Immune Globulin (VIG)

Vaccinia immune globulin (VIG) is created by pooling the blood sample of people who have received the smallpox vaccine. These people are separated and cleaned because they can acquire antibodies in response to the smallpox vaccine. [31]

CONCLUSION

The newest pox virus appears to be comparable to the smallpox virus, which causes a serious life-threatening illness in humans. The illness was firstly reported in test center or laboratory monkeys in 1958, nonetheless, but the instance in first human was discovered in 1970 in a 9-month-child in the Democratic Republic of the Congo (DRC). Before 2003, Outside of Africa, the virus had not been detected. Biological conflict and the possibility of biological agents cannot be ruled out, thus a deeper understanding of the monkeypox disease and other comparable germs might help with emergency management. There are still a lot of enquiries about human sickness, animal stock, and the virus itself. As a result, gaining a better knowledge of this common zoonosis will aid in developing better preventative techniques and relieving human sickness.

Reference

- Grant R, Nguyen LB, Breban R. Modelling human-to-human transmission of monkeypox. Bulletin of the World Health Organization. 2020 Sep 1;98(9):638.
- Guagliardo SA, Reynolds MG, Kabamba J, Nguete B, Shongo Lushima R, Wemakoy OE, McCollum AM. Sounding the alarm: Defining thresholds to trigger a public health response to monkeypox. PLoS Neglected Tropical Diseases. 2018 Dec 20;12(12):e0007034.
- Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, Oyeyemi A, Etebu EN, Ihekweazu C. The 2017 human monkeypox outbreak in Nigeria—report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS One. 2019 Apr 17;14(4):e0214229.
- Simpson K, Heymann D, Brown CS, Edmunds WJ, Elsgaard J, Fine P, Hochstein H, Hoff NA, Green A, Ihekweazu C, Jones TC. Human monkeypox—After 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020 Jul 14;38(33):5077-81.
- Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, Cummings EC, Kuteyi OE, Eke RE, Titus JB, Smith EA. Human monkeypox. Bulletin of the World Health Organization. 1972;46(5):569.
- Walker M. Monkeypox Virus Hosts and Transmission Routes: A Systematic Review of a Zoonotic Pathogen.
- Rimoin AW, Mulembakani PM, Johnston SC, Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences. 2010 Sep 14;107(37):16262-7.
- Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J. Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases. 2022 May 24.



- Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS neglected tropical diseases*. 2019 Oct 16;13(10):e0007791.
- Adalja A, Inglesby T. A Novel International Monkeypox Outbreak. *Annals of Internal Medicine*. 2022 May 24.
- Sklenovska N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. *Frontiers in public health*. 2018 Sep 4;6:241.
<https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385>
- Pal M, Mengstie F, Kandi V. Epidemiology, Diagnosis, and Control of Monkeypox Disease: A comprehensive Review. *American Journal of Infectious Diseases and Microbiology*. 2017;5(2):94-.
- Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. *PLoS neglected tropical diseases*. 2022 Feb 11;16(2):e0010141.
- Moore M, Zahra F. Monkeypox. InStatPearls [Internet] 2021 Sep 8. StatPearls Publishing.
- Yinka-Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, Mohammed A, Agenyi J, Etebu EN, Numbere TW, Ndoreraho A. Reemergence of human monkeypox in Nigeria, 2017. *Emerging infectious diseases*. 2018 Jun;24(6):1149.
- Mahase E. Monkeypox: What do we know about the outbreaks in Europe and North America?.
- Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. *Emerging Infectious Diseases*. 2021 Apr;27(4):1007.
- Swami, Aravinda. (2018). A BRIEF REVIEW ON MONKEY POX ILLNESS.
- McCollum AM, Damon IK. Human monkeypox. *Clinical infectious diseases*. 2014 Jan 15;58(2):260-7.
- ASSESSMENT RR. Monkeypox multi-country outbreak.
- Weinstein RA, Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. *Clinical infectious diseases*. 2005 Dec 15;41(12):1765-71.
- Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. *Viruses*. 2020 Nov;12(11):1257.
- Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. *Infectious Disease Clinics*. 2019 Dec 1;33(4):1027-43.
- Brown K, Leggat PA. Human monkeypox: current state of knowledge and implications for the future. *Tropical medicine and infectious disease*. 2016 Dec;1(1):8.
- Stittelaar KJ, Neyts J, Naesens L, Van Amerongen G, Van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. *Nature*. 2006 Feb;439(7077):745-8.
- Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J. Clinical features and management of human monkeypox: a retrospective observational study in the UK. *The Lancet Infectious Diseases*. 2022 May 24.
- Zabawski Jr EJ. A review of topical and intralesional cidofovir. *Dermatology Online Journal*. 2000 Sep 1;6(1):3-.
- Centers for Disease Control and Prevention. Updated interim CDC guidance for use of smallpox vaccine, cidofovir, and vaccinia immune globulin (VIG) for prevention and treatment in the setting of an outbreak of monkeypox infections. Atlanta, GA: CDC. 2003 Jun 25.
- Sbrana E, Jordan R, Hraby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, Ap DR, Tesh RB. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. *The American journal of tropical medicine and hygiene*. 2007 Apr 1;76(4):768-73.
- Centers for Disease Control and Prevention. Updated interim CDC guidance for use of smallpox vaccine, cidofovir, and vaccinia immune globulin (VIG) for prevention and treatment in the setting of an outbreak of monkeypox infections. Atlanta, GA: CDC. 2003 Jun 25.
- Karama, R. S. ., Simon, N. H., Chatterjee, A., Aswasthi, S., Akinola, A., Acharya, S., Praveen, U., Lachyan, A., Khan, S., & Gangurde, P. (2022). Effectiveness of video-based teaching program to assess the knowledge of young mothers in identifying developmental milestones in Delhi NCR, India. *International Journal of Health Sciences*, 6(S1), 12194–12204.
<https://doi.org/10.53730/ijhs.v6nS1.8281>
- Akinola, A., Karama, R., & Rajput, M. (2022). Awareness of natural breastfeeding milk among mothers and the importance of colostrum within the first hour of birth in India. *International Journal Of Community Medicine And Public Health*, 9(7), 2992-2997.
doi:<http://dx.doi.org/10.18203/2394-6040.ijcmph20221772>

